JP4857748B2 - Quazepam manufacturing method - Google Patents

Quazepam manufacturing method Download PDF

Info

Publication number
JP4857748B2
JP4857748B2 JP2005354521A JP2005354521A JP4857748B2 JP 4857748 B2 JP4857748 B2 JP 4857748B2 JP 2005354521 A JP2005354521 A JP 2005354521A JP 2005354521 A JP2005354521 A JP 2005354521A JP 4857748 B2 JP4857748 B2 JP 4857748B2
Authority
JP
Japan
Prior art keywords
quazepam
reagent
oxoquazepam
solution
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2005354521A
Other languages
Japanese (ja)
Other versions
JP2007153848A (en
Inventor
道康 星
広幸 北
伸 池田
良信 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dai Nippon Printing Co Ltd
Original Assignee
Dai Nippon Printing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dai Nippon Printing Co Ltd filed Critical Dai Nippon Printing Co Ltd
Priority to JP2005354521A priority Critical patent/JP4857748B2/en
Publication of JP2007153848A publication Critical patent/JP2007153848A/en
Application granted granted Critical
Publication of JP4857748B2 publication Critical patent/JP4857748B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

本発明は、睡眠障害改善剤として有用な下式Iで示される一般名:クアゼパム(化学名:7−Chloro−5−(2−fluorophenyl)−1,3−dihydro−1−(2,2,2−trifluoroethyl)−2H−−1,4−benzodiazepine−2−thione)の工業的に有益な製造法に関するものである。

Figure 0004857748
The present invention is useful as a sleep disorder ameliorating agent and is represented by the following general name: quazepam (chemical name: 7-Chloro-5- (2-fluorophenyl) -1,3-dihydro-1- (2,2,2) 2-trifluoroethyl) -2H--1,4-benzodiapine-2-thione).
Figure 0004857748

クアゼパムの製造方法としてはオキソクアゼパム(化学名:7−Chloro−5−(2−fluorophenyl)−1,3−dihydro−1−(2,2,2−trifluoroethyl)−2H−1,4−benzodiazepine−2−one)にチオン基を導入する方法が知られている。具体的にはジオキサンに溶かした溶液に五硫化リンを添加し4時間還流するという製造法である。(特許文献1)   As a method for producing quazepam, oxoquazepam (chemical name: 7-Chloro-5- (2-fluorophenyl) -1,3-dihydro-1- (2,2,2-trifluoroethyl) -2H-1,4-benzodiapine- A method of introducing a thione group into 2-one) is known. Specifically, it is a production method in which phosphorus pentasulfide is added to a solution dissolved in dioxane and refluxed for 4 hours. (Patent Document 1)

本発明者らがこれを追試実験した結果、目的の反応とは別に溶媒であるジオキサンと五硫化リンが反応し下式IIIで表される1,4−Dithiane−1−oxideを生成していることが判明した。スルフィド類は特有の臭気を持ち、おおむね悪臭を示すが、この物質も揮発性の異臭を発する化合物であり、原体中に残存し原体そのものや、クアゼパム製剤におけるにおいの原因となり医薬品としての品質上重大な問題となる。一方、工業的製造という視点においては、ジオキサンは人に対する健康影響で発がん性を示す可能性があることから製造作業者の安全を確保する為には使用を避けることが望ましい。また、特許文献1では反応終了後に濃縮してシリカゲル処理しているが、この操作中に残存する余剰の硫化試薬が少しずつ分解し硫化水素ガスを発生している。このガスは有害性が高いことからガス発生が少ない製造法が望まれる。ガス発生抑制の為に、硫化試薬を水酸化アルカリ水溶液等を添加して分解することが挙げられるが、ジオキサンの如き水溶性溶媒で反応せしめた後に、硫化試薬分解の為アルカリ水溶液を加えると、クアゼパムそのものの分解を招くという問題がある。

Figure 0004857748
特公昭56−28914 As a result of additional experiments conducted by the present inventors, a solvent, dioxane, and phosphorus pentasulfide react with each other to produce 1,4-Dithiane-1-oxide represented by the following formula III. It has been found. Sulfides have a specific odor and generally have a bad odor, but this substance is also a compound that emits a volatile odor, which remains in the drug substance and causes odor in the drug substance or quazepam preparations. It becomes a serious problem. On the other hand, from the viewpoint of industrial production, it is desirable to avoid the use of dioxane in order to ensure the safety of manufacturing workers because dioxane may exhibit carcinogenicity due to health effects on humans. Further, in Patent Document 1, after the reaction is completed, the silica gel is concentrated and the surplus sulfur reagent remaining during the operation is gradually decomposed to generate hydrogen sulfide gas. Since this gas is highly harmful, a production method with less gas generation is desired. In order to suppress gas generation, the sulfurizing reagent can be decomposed by adding an aqueous alkali hydroxide solution, etc., but after reacting with a water-soluble solvent such as dioxane, an alkaline aqueous solution is added to decompose the sulfurizing reagent. There is a problem in that it causes degradation of kuazepam itself.
Figure 0004857748
Shoko 56-28914

本発明の目的は、高品質のクアゼパムを製造する工業的にすぐれた方法を提供することにある。   It is an object of the present invention to provide an industrially superior method for producing high quality quazepam.

本発明者らはオキソクアゼパムにチオン基を導入するクアゼパムの製造法において、五硫化リンなどの硫化試薬に安定で、労働安全衛生の観点から安心して使用できる溶媒を鋭意検討した結果、トルエンが優れていることを見出した。本発明の製造法では硫化試薬と反応溶媒に起因する不純物の発生が無く、不快なにおいの無い原体が得られる。反応後に硫化試薬の分解を行うが、水性溶媒の場合は添加するアルカリ水溶液に直接クアゼパムが接触すると分解がおきることから品質低下は免れない。本発明の方法によればトルエン溶媒層にクアゼパムが溶解しているので品質の劣化無しに、残存する硫化試薬の分解を行うことができるという多大な効果が期待できる。   As a result of intensive investigation of a solvent that is stable to a sulfurizing reagent such as phosphorus pentasulfide and that can be used with peace of mind from the viewpoint of occupational safety and health, the present inventors have found that toluene is excellent in the production method of quazepam that introduces a thione group into oxoquazepam. I found out. In the production method of the present invention, there is no generation of impurities due to the sulfurizing reagent and the reaction solvent, and a raw material having no unpleasant odor is obtained. Although the sulfurizing reagent is decomposed after the reaction, in the case of an aqueous solvent, degradation occurs when quazepam is brought into direct contact with the alkaline aqueous solution to be added, so that deterioration in quality is inevitable. According to the method of the present invention, since quazepam is dissolved in the toluene solvent layer, a great effect can be expected that the remaining sulfurizing reagent can be decomposed without deterioration in quality.

すなわち本発明は以下の手段によって達成される。
(1)トルエン溶媒、塩基存在下、硫化試薬にて式IIで表されるオキソクアゼパムにチオン基を導入し、次いで反応液にアルカリ水溶液を投入することにより余剰の硫化試薬を分解することを特徴とする式Iで表されるクアゼパムの製造法。

Figure 0004857748
Figure 0004857748
(2)
硫化試薬にローソン試薬または五硫化リンを使用することを特徴とする(1)に記載の製造法。
(3)
アルカリ水溶液に水酸化ナトリウム水溶液を使用することを特徴とする(1)または(2)に記載の製造法。 That is, the present invention is achieved by the following means.
(1) In the presence of a toluene solvent and a base, a thione group is introduced into the oxoquazepam represented by the formula II with a sulfurizing reagent, and then an excess aqueous reagent is decomposed by introducing an alkaline aqueous solution into the reaction solution. A process for producing quazepam represented by the formula I:
Figure 0004857748
Figure 0004857748
(2)
The production method according to (1), wherein Lawson reagent or phosphorus pentasulfide is used as the sulfurization reagent.
(3)
The method according to (1) or (2), wherein an aqueous sodium hydroxide solution is used as the alkaline aqueous solution.

本発明によれば、工業的生産において高品質のクアゼパムを製造できる。   According to the present invention, high-quality quazepam can be produced in industrial production.

オキソクアゼパムは特公平2−24807に記載の方法により製造できる化合物であり、オキソクアゼパムにチオン基を導入することでクアゼパムを製造することができる。クアゼパムを製造するための硫化試薬としては五硫化リン、ローソン試薬(2,4−Bis(4−methoxyphenyl)−1,3,2,4−dithiadiphosphetane 2,4−disulfide)が好ましくその使用量はオキソクアゼパムに対して0.5〜1.5倍モルである。添加する塩基種としてはピリジンやトリエチルアミンなどの有機塩基、アルカリ金属水酸化物やアルカリ金属炭酸塩などの無機塩基などが使用可能である。添加する塩基の使用量はオキソクアゼパムに対して0.5〜1.5倍モルである。   Oxoquazepam is a compound that can be produced by the method described in Japanese Patent Publication No. 2-24807, and quazepam can be produced by introducing a thione group into oxoquazepam. The sulfurizing reagent for producing quazepam is preferably phosphorus pentasulfide or Lawesson's reagent (2,4-bis (4-methoxyphenyl) -1,3,2,4-dithiadiphosphatane 2,4-disulphide). It is 0.5-1.5 times mole with respect to quazepam. As the base species to be added, organic bases such as pyridine and triethylamine, inorganic bases such as alkali metal hydroxides and alkali metal carbonates, and the like can be used. The amount of the base to be added is 0.5 to 1.5 times mol with respect to oxoquazepam.

オキソクアゼパム、硫化試薬、塩基、トルエンを混合してから加温して反応させる。主に硫化試薬が不溶解物として残存した状態で加温攪拌を続ける。反応温度は、低すぎると反応に時間がかかることから好ましくは100℃〜110℃である。反応時間は温度によって異なるが10時間〜20時間程度である。   Oxoquazepam, sulfurizing reagent, base, and toluene are mixed and then heated for reaction. Heating and stirring are continued mainly with the sulfurizing reagent remaining as an insoluble substance. The reaction temperature is preferably 100 ° C. to 110 ° C. because the reaction takes time if it is too low. The reaction time varies depending on the temperature, but is about 10 to 20 hours.

反応は高速液体クロマトグラフィーにてモニタリングすることが可能であり、オキソクアゼパムがほぼ消失したところで反応液を室温に戻し反応終了とする。反応液にアルカリ水溶液を滴下しながら攪拌して残存している硫化試薬を安全に分解処理することができる。アルカリ水溶液としては安価な水酸化ナトリウム水溶液が好ましい。   The reaction can be monitored by high performance liquid chromatography. When oxoquazepam has almost disappeared, the reaction solution is returned to room temperature to complete the reaction. The remaining sulfurizing reagent can be safely decomposed by stirring while dropping an aqueous alkali solution into the reaction solution. As the alkaline aqueous solution, an inexpensive sodium hydroxide aqueous solution is preferable.

硫化試薬に五硫化リンを使用した場合、分解物は水硫化ナトリウムで、この物質は水層中に溶解したままであり有害なガスを発生させることなく後処理することができる。有機層にクアゼパムが溶解しているが、クアゼパムの分解はほとんど無く、余剰の硫化試薬を選択的に分解することができる。   When phosphorus pentasulfide is used as the sulfurizing reagent, the decomposition product is sodium hydrosulfide, and this substance remains dissolved in the aqueous layer and can be post-treated without generating harmful gases. Quazepam is dissolved in the organic layer, but there is almost no decomposition of quazepam, and the surplus sulfurizing reagent can be selectively decomposed.

以下、実施例によって本発明を具体的に説明するが、本発明は、これらの実施例に限定されるものではない。
実施例における液体クロマトグラフィー純度は、下記条件にて液体クロマトグラフィー分析を行い、各成分ピークの面積%を用いたものであり純度の指標とした。
装置:LC−2000Plus series(日本分光株式会社)
カラム:YMCPACK ODS−AM
移動層:アセトニトリル/水/メタノール=11/5/4の混合液
検出波長:220nm
また1,4−Dithiane−1−oxide含量は、上記条件の液体クロマトグラフィーにて定量した。
EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not limited to these Examples.
The liquid chromatography purity in the examples was obtained by performing liquid chromatography analysis under the following conditions and using the area% of each component peak, and was used as an index of purity.
Apparatus: LC-2000 Plus series (JASCO Corporation)
Column: YMCPACK ODS-AM
Moving layer: A mixture of acetonitrile / water / methanol = 11/5/4 Detection wavelength: 220 nm
The 1,4-Dithiane-1-oxide content was quantified by liquid chromatography under the above conditions.

参考例1
攪拌装置を備え付けた5L反応容器にてオキソクアゼパム250g(0.7mol)をジオキサン2.5Lに溶解した後、五硫化リン150g(0.7mol)を加えて、120℃にて攪拌しながら10時間還流した。高速液体クロマトグラフィーにてオキソクアゼパムが2%以下であることを確認後、溶媒を減圧留去した。残滓をジクロロメタン溶媒にてシリカゲルクロマトグラフィー精製後、ジクロロメタンとヘキサンの混合液から晶出せしめた。結晶をろ過、乾燥してクアゼパムを黄色結晶として得た。特有のにおいを発する結晶であった。収量72.5g、収率27.9%、1,4−Dithiane−1−oxide含量80ppm
H−NMR(CDCl)δ(ppm):4.2(1H,d),4.4(1H,m),5.5(1H,d),6.3(1H,m),7.1−7.7(7H,m)
Reference example 1
In a 5 L reaction vessel equipped with a stirrer, 250 g (0.7 mol) of oxoquazepam was dissolved in 2.5 L of dioxane, and then 150 g (0.7 mol) of phosphorus pentasulfide was added and stirred at 120 ° C. for 10 hours. Refluxed. After confirming that oxoquazepam was 2% or less by high performance liquid chromatography, the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography using dichloromethane solvent, and then crystallized from a mixture of dichloromethane and hexane. The crystals were filtered and dried to obtain quazepam as yellow crystals. It was a crystal that gave off a unique odor. Yield 72.5 g, Yield 27.9%, 1,4-Dithiane-1-oxide content 80 ppm
1 H-NMR (CDCl 3 ) δ (ppm): 4.2 (1H, d), 4.4 (1H, m), 5.5 (1H, d), 6.3 (1H, m), 7 .1-7.7 (7H, m)

参考例2
参考例1の結晶をろ過したろ液を濃縮後、減圧蒸留(0.5mmHg,75℃)し1,4−Dithiane−1−oxide0.5gを単離した。
H−NMR(CDCl)δ(ppm):3.0(2H,t),4.1(2H,t)
MASS m/z 136
Reference example 2
The filtrate obtained by filtering the crystals of Reference Example 1 was concentrated and then distilled under reduced pressure (0.5 mmHg, 75 ° C.) to isolate 0.5 g of 1,4-Dithiane-1-oxide.
1 H-NMR (CDCl 3 ) δ (ppm): 3.0 (2H, t), 4.1 (2H, t)
MASS m / z 136

実施例1
攪拌装置を備え付けた5L反応容器にてオキソクアゼパム250g(0.7mol)をトルエン2.5Lに溶解した後、五硫化リン150g(0.7mol)、炭酸水素ナトリウム86g(1.0mol)を加えて、110℃にて攪拌しながら10時間還流した。高速液体クロマトグラフィーにてオキソクアゼパムが2%以下であることを確認後、25%水酸化ナトリウム水溶液900gを滴下して余剰の五硫化リンを分解した後、水層を分離し、溶媒を減圧留去した。残滓をジクロロメタン溶媒にてシリカゲルクロマトグラフィー精製後、ジクロロメタンとヘキサンの混合液から晶出せしめた。結晶をろ過、乾燥してクアゼパムを黄色結晶として得た。結晶ににおいはなかった。収量158.5g、収率63.2%、1,4−Dithiane−1−oxideは検出されなかった。
H−NMR(CDCl)δ(ppm):4.2(1H,d),4.4(1H,m),5.5(1H,d),6.3(1H,m),7.1−7.7(7H,m)
Example 1
In a 5 L reaction vessel equipped with a stirrer, 250 g (0.7 mol) of oxoquazepam was dissolved in 2.5 L of toluene, and then 150 g (0.7 mol) of phosphorus pentasulfide and 86 g (1.0 mol) of sodium bicarbonate were added. The mixture was refluxed for 10 hours with stirring at 110 ° C. After confirming that oxoquazepam is 2% or less by high performance liquid chromatography, 900 g of 25% aqueous sodium hydroxide solution was added dropwise to decompose excess phosphorus pentasulfide, the aqueous layer was separated, and the solvent was distilled under reduced pressure. Left. The residue was purified by silica gel chromatography using dichloromethane solvent, and then crystallized from a mixture of dichloromethane and hexane. The crystals were filtered and dried to obtain quazepam as yellow crystals. There was no smell in the crystals. The yield was 158.5 g, the yield was 63.2%, and 1,4-Dithiane-1-oxide was not detected.
1 H-NMR (CDCl 3 ) δ (ppm): 4.2 (1H, d), 4.4 (1H, m), 5.5 (1H, d), 6.3 (1H, m), 7 .1-7.7 (7H, m)

Claims (3)

トルエン溶媒、塩基存在下、硫化試薬にて式IIで表されるオキソクアゼパムにチオン基を導入し、次いで反応液にアルカリ水溶液を投入することにより余剰の硫化試薬を分解することを特徴とする式Iで表されるクアゼパムの製造法。
Figure 0004857748
Figure 0004857748
A formula characterized by decomposing excess sulfidation reagent by introducing a thione group into oxoquazepam represented by formula II with a sulfurization reagent in the presence of a toluene solvent and a base, and then adding an aqueous alkaline solution to the reaction solution. A method for producing quazepam represented by I.
Figure 0004857748
Figure 0004857748
硫化試薬にローソン試薬または五硫化リンを使用することを特徴とする請求項1に記載の製造法。   The production method according to claim 1, wherein Lawson's reagent or phosphorus pentasulfide is used as the sulfurizing reagent. アルカリ水溶液に水酸化ナトリウム水溶液を使用することを特徴とする請求項1または2に記載の製造法。   The method according to claim 1 or 2, wherein an aqueous sodium hydroxide solution is used as the alkaline aqueous solution.
JP2005354521A 2005-12-08 2005-12-08 Quazepam manufacturing method Active JP4857748B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005354521A JP4857748B2 (en) 2005-12-08 2005-12-08 Quazepam manufacturing method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005354521A JP4857748B2 (en) 2005-12-08 2005-12-08 Quazepam manufacturing method

Publications (2)

Publication Number Publication Date
JP2007153848A JP2007153848A (en) 2007-06-21
JP4857748B2 true JP4857748B2 (en) 2012-01-18

Family

ID=38238650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005354521A Active JP4857748B2 (en) 2005-12-08 2005-12-08 Quazepam manufacturing method

Country Status (1)

Country Link
JP (1) JP4857748B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH556852A (en) * 1970-08-07 1974-12-13 Scherico Ltd PROCESS FOR THE PREPARATION OF NEW 1,4-BENZODIAZEPINES.
JPH01158455A (en) * 1988-11-04 1989-06-21 Fuji Photo Film Co Ltd Photoconductive composition
JP3982738B2 (en) * 2001-03-14 2007-09-26 財団法人理工学振興会 Synthesis of 2-thiouridine analogs

Also Published As

Publication number Publication date
JP2007153848A (en) 2007-06-21

Similar Documents

Publication Publication Date Title
McMaster et al. Radical-mediated reduction of the dithiocarbamate group under tin-free conditions
HUE025730T2 (en) Process for the preparation of statins in the presence of base
JP4857748B2 (en) Quazepam manufacturing method
KR101056461B1 (en) Manufacturing method of heterocyclic mercapto compound
KR100491318B1 (en) Method for preparing oltipraz
RU2155758C2 (en) Method of preparing 1,2-benzothiazolin-3-ones (versions)
CN108430968A (en) Prepare the industrial technology of three thia -12- azepines heneicosane -5- ammoniums (E) -3- carboxy acrylic salt of (5S, 10S) -10- benzyl -16- methyl-1 1,14,18- trioxy- -15,17,19- trioxas -2,7,8-
CN108101863B (en) Method for synthesizing benzothiazole-2-ketone derivative by using carbonyl sulfide and disulfide as raw materials
JP4463209B2 (en) Method for producing optically active amine compound
FR2486527A1 (en) PROCESS FOR THE PREPARATION OF N-CYCLOHEXYLBENZOTHIAZOLE-2-SULFENAMIDE
KR20030023765A (en) Catalytic process for the preparation of thiazole derivatives
EP0547092B1 (en) Process for preparing 2-methyl-3,5-dialkylpyridines by dealkylation with sulfur
JP2010208990A (en) Method of producing sulfone compound
JP4967401B2 (en) Oxoquazepam production method
JP6464970B2 (en) Method for producing oxaziridine compound
JPS5840546B2 (en) 2- Benzimidazole carbamic acid alkyl ester
JP2008536899A (en) Method for producing alkoxyamine by photolysis of dithiocarbamate
JP4551722B2 (en) Method for producing pentabromothiophenol
JP4901481B2 (en) Method for producing thiocarbamate derivative
KR20070114343A (en) Process for preparation of bicalutamide
JP2007290987A (en) Method for producing chlorothiol formate
JP2010208988A (en) Method of producing sulfoxide compound
KR101621754B1 (en) PROCESS OF PREPARING α-KETO (CYANOMETHYLENE)TRIPHENYLPHOSPHORANES USING XANTHATE COMPOUNDS
RU2152396C1 (en) Method of synthesis of tri-(2,4-di-tertiary-butylphenyl)-phosphite
JPH07267950A (en) Production of 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazole-4-amine or its acid-added salt

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111017

R150 Certificate of patent or registration of utility model

Ref document number: 4857748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141111

Year of fee payment: 3